Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 1Phase 1/2 1

Status

Completed 4Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 19INDUSTRY 8NIH 1NETWORK 1

Study Type

Interventional 8

Sponsor

Cancer Type

Lymphoid 2Breast 2Tumor-Agnostic 1Thoracic 1Genitourinary 1

Conditions

Recurrence 1Neoplasms 1Muscle Invasive Bladder Cancer 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1DLBCL 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Malignancies 1Advanced Metastatic Breast Cancer 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
INDUSTRY × vistusertib × Clear all
NCT01597388 2026-02-24

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

AstraZeneca

Phase 1 Completed
99 enrolled 61 charts
Breast

Advanced Metastatic Breast Cancer

NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting
117 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

NCT03334617 2025-10-27

HUDSON

AstraZeneca

Phase 2 Active not recruiting
528 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02398747 2024-12-17

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
28 enrolled

Advanced Solid Malignancies

NCT02599714 2024-06-06

PASTOR

AstraZeneca

Phase 1 Completed
54 enrolled
Breast

Breast Neoplasms

NCT03205046 2021-01-06

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Acerta Pharma BV

Phase 1/2 Terminated
25 enrolled 11 charts
Lymphoid

DLBCL

NCT02780830 2016-09-15

INHIBITOR

AstraZeneca

Phase 1 Withdrawn
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01026402 2016-02-11

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

AstraZeneca

Phase 1 Completed
172 enrolled 35 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡